The placebo effect in oncology trials and the criteria for approving drugs

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC

ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL

ASH 2022: Multiple myeloma roundup

Breast cancer patients who interrupted endocrine therapy to pursue pregnancy did not have worse short-term recurrence rates

Interruption of endocrine therapy in young breast cancer patients does not increase the risk of short-term relapse

Genetic profiling identifies patients who can omit radiation therapy after breast-conserving surgery

PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival compared to Tac/MTX in graft-versus-host disease 

Effective treatment of low risk acute GVHD with itacitinib monotherapy

Longest follow-up of patients with early breast cancer shows radiotherapy does not improve survival after 30 years

Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma

Add-on parsaclisib demonstrates improvement in symptoms and SV in MV patients having a suboptimal response to ruxolitinib